Robert Swanton Biography and Net Worth

Director of Bicycle Therapeutics

Dr. Swanton leads the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute. His research is focused on how tumors evolve over space and time, and he has authored over 250 papers developing an understanding of branching evolutionary histories of solid tumors, processes that drive cancer cell-to-cell variation, and the impact of cancer diversity on effective immune surveillance and clinical outcome.

Dr. Swanton is a fellow of the Royal Society, a fellow of the Royal College of Physicians and a fellow of the Academy of Medical Sciences. He completed his M.D. and Ph.D. training at the Imperial Cancer Research Fund Laboratories.

What is Robert Charles Swanton's net worth?: The estimated net worth of Robert Charles Swanton is at least $75.89 thousand as of October 2nd, 2025. Dr. Swanton owns 15,487 shares of Bicycle Therapeutics stock worth more than $75,886 as of May 5th. This net worth evaluation does not reflect any other assets that Dr. Swanton may own. Learn More about Robert Charles Swanton's net worth.
How do I contact Robert Charles Swanton?: The corporate mailing address for Dr. Swanton and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Robert Charles Swanton's contact information.
Has Robert Charles Swanton been buying or selling shares of Bicycle Therapeutics?: Robert Charles Swanton has not been actively trading shares of Bicycle Therapeutics over the course of the past ninety days. Most recently, Robert Charles Swanton sold 102 shares of the business's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $8.55, for a transaction totalling $872.10. Following the completion of the sale, the director now directly owns 15,487 shares of the company's stock, valued at $132,413.85. Learn More on Robert Charles Swanton's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Michael Skynner (CTO), Robert Swanton (Director), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, insiders at the sold shares 29 times. They sold a total of 64,634 shares worth more than $431,887.68. The most recent insider tranaction occured on April, 6th when CFO Travis Alvin Thompson sold 102 shares worth more than $515.10. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 4/6/2026.

Robert Charles Swanton Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/2/2025	Sell	102	$8.55	$872.10	15,487

Robert Charles Swanton Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $4.90

$4.83

$5.08

50 Day Range

MA: $5.02

$4.31

$5.73

2 Week Range

Now: $4.90

$4.24

$9.36

Volume

318,718 shs

Average Volume

420,077 shs

Market Capitalization

$341.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56